- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02650401
Tutkimus entrektinibistä (Rxdx-101) lapsilla ja nuorilla, joilla on paikallisesti edennyt tai metastaattinen kiinteä tai primaarinen keskushermoston kasvain ja/tai joilla ei ole tyydyttäviä hoitovaihtoehtoja (STARTRK-NG)
Vaihe 1/2, avoin, annoksen suurennus- ja laajennustutkimus entrektinibistä (Rxdx-101) lapsipotilailla, joilla on paikallisesti edennyt tai metastaattinen kiinteä tai primaarinen keskushermoston kasvain ja/tai joilla ei ole tyydyttäviä hoitovaihtoehtoja
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Madrid, Espanja, 28009
- Hospital Infantil Universitario Nino Jesus
-
-
-
-
-
Hong Kong, Hong Kong, 00000
- Hong Kong Children's Hospital
-
-
-
-
Lombardy
-
Milan, Lombardy, Italia, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Beijing, Kiina
- Beijing Children's Hospital, Capital Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kiina, 200082
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
-
-
-
-
Lyon, Ranska, 69373
- Centre Leon Berard
-
Marseille, Ranska, 13385
- Hôpital de la Timone, Oncologie Pédiatrique
-
-
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Saksa, 69120
- Universitaetsklinikum Heidelberg
-
-
-
-
-
London, Yhdistynyt kuningaskunta, SW3 6JJ
- Royal Marsden Hospital (Sutton)
-
Newcastle upon Tyne, Yhdistynyt kuningaskunta, NE1 4LP
- Royal Victoria Infirmary
-
-
-
-
California
-
La Jolla, California, Yhdysvallat, 92093-0706
- University of California San Diego
-
San Francisco, California, Yhdysvallat, 94158
- UCSF Benioff Children's Hospital
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30322
- Egleston Children's Hospital at Emory University Atlanta
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60637
- University of Chicago
-
-
Maryland
-
Baltimore, Maryland, Yhdysvallat, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02215
- Dana Farber Cancer Institute
-
-
Missouri
-
St Louis, Missouri, Yhdysvallat, 63110
- Washington University,St. Louis Children's Hospital
-
-
New York
-
New York, New York, Yhdysvallat, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Yhdysvallat, 43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland, Oregon, Yhdysvallat, 97239
- Oregon Health & Science Uni
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Memphis, Tennessee, Yhdysvallat, 38105
- St. Jude Children'S Research Hospital
-
-
Texas
-
Houston, Texas, Yhdysvallat, 77030
- Texas Children's Cancer and Hematology Center
-
-
Utah
-
Salt Lake City, Utah, Yhdysvallat, 84113
- Primary Children's Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Disease status:
-
Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1
-
Phase 2 portion:
- Part B: Participants must have measurable or evaluable disease, as defined by RANO
- Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
- Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
- Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
-
-
Tumor type:
-
Phase 1 portion:
* Part A: Relapsed or refractory extracranial solid tumors
-
Phase 2 portion
- Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
- Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
-
-
Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse
-
Archival tumor tissue from diagnosis or, preferably, at relapse
-
Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks
-
Prior therapy: Participants must have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive
-
Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment
-
Adequate organ and neurologic function
-
Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.
-
For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug
Exclusion Criteria:
- Receiving other experimental therapy
- Known congenital long QT syndrome
- History of recent (3 months) symptomatic congestive heart failure or ejection fraction ≤50% at screening
- Known active infections
- Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
- Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
- Prior treatment with approved or investigational TRK or ROS1 inhibitors
- Known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product
- Patients with NB with bone marrow space-only disease
- Incomplete recovery from acute effects of any surgery prior to treatment.
- Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
- Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Extracranial solid tumors harboring NTRK1/2/3,
Arm closed for further enrollment ROS1, ALK non-gene fusion molecular alterations Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Muut nimet:
|
|
Active Comparator: CNS tumors harboring- NTRK1/2/3, ROS1, ALK
Arm closed for further enrollment molecular alterations, including gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Muut nimet:
|
|
Active Comparator: Neuroblastoma
Arm closed for further enrollment Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Muut nimet:
|
|
Active Comparator: Non-neuroblastoma, extracranial solid tumors
Arm closed for further enrollment harboring - NTRK1/2/3, ROS1, ALK gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Muut nimet:
|
|
Active Comparator: Any participant unable to swallow capsules
Arm closed for further enrollment Any participant who otherwise meet all other eligibility criteria Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Muut nimet:
|
|
Active Comparator: Expansion: CNS tumors harboring NTRK1/2/3, ROS1
gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Muut nimet:
|
|
Active Comparator: Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1
NTRK 1,2,3 and ROS1 fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Aikaikkuna: Approximately 6 months
|
Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03) |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Aikaikkuna: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Aikaikkuna: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
Aikaikkuna: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
Aikaikkuna: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Cohort B: Objective Response Rate (ORR)
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR |
Approximately 6 months
|
|
Cohort D: ORR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR |
Approximately 6 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
Aikaikkuna: Approximately 24 months
|
AE, ECG and Labs assessed by NCI CTCAE v4.03 |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F1 Formulation
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using minitablets/F15
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F1 Formulation
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using minitablets/F15
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F1 Formulation
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F06 Formulation given intact
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using minitablets/F15
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F1 Formulation
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F06 Formulation given intact
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F06 Formulation administered via feeding tube
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using minitablets/F15
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F1 Formulation
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using minitablets/F15
Aikaikkuna: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Cohort A, D, or E: Clinical Benefit Rate (CBR)
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: CBR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: CBR
Aikaikkuna: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Progression-free Survival (PFS)
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: PFS
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: PFS
Aikaikkuna: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Overall Survival (OS)
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 |
Approximately 6 months
|
|
Cohort B or E: OS
Aikaikkuna: Approximately 6 months
|
Assessed by RANO |
Approximately 6 months
|
|
Cohort A, D, or E: ORR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: ORR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: ORR
Aikaikkuna: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Time to response (TTR)
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: TTR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: TTR
Aikaikkuna: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Duration of Response (DOR)
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: DOR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: DOR
Aikaikkuna: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR
Aikaikkuna: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Aikaikkuna: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Clinical Trials, Hoffmann-La Roche
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 Oct 3;24(10):1776-1789. doi: 10.1093/neuonc/noac087.
- Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
- Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvioitu)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
- Pediatriset
- Relapsi
- Tulenkestävä
- Ewingin sarkooma
- Medulloblastooma
- Kiinteä kasvain
- Metastaattinen syöpä
- Sarkooma
- Neuroblastooma
- Papillaarinen kilpirauhassyöpä
- Keskushermoston kasvaimet
- ROS1
- NTRK
- ALK
- Aivokasvaimet
- NTRK1
- NTRK2
- NTRK3
- TRK
- Tyrosiinikinaasi
- Geenien uudelleenjärjestely
- Infantiili fibrosarkooma
- Sekretiivinen rintasyöpä
- Synnynnäinen mesoblastinen nefroma
- Pontinen gliooma
- Gliaaliset kasvaimet
- Sylkirauhassyöpä (MASC)
- Wilmsin kasvain (anaplastinen)
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Endokriinisen järjestelmän sairaudet
- Suun sairaudet
- Stomatognaattiset sairaudet
- Aivojen sairaudet
- Keskushermoston sairaudet
- Hermoston sairaudet
- Patologiset prosessit
- Urogenitaaliset kasvaimet
- Neoplasmat sivustoittain
- Neoplasmat
- Miesten urogenitaaliset sairaudet
- Munuaissairaudet
- Urologiset sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet ja raskauden komplikaatiot
- Sairauden ominaisuudet
- Geneettiset sairaudet, synnynnäiset
- Neoplasmat histologisen tyypin mukaan
- Kilpirauhasen kasvaimet
- Endokriinisten rauhasten kasvaimet
- Pään ja kaulan kasvaimet
- Kasvaimet, rauhas- ja epiteelikasvaimet
- Adenokarsinooma
- Neoplastiset prosessit
- Urologiset kasvaimet
- Karsinooma
- Neoplasmat, neuroepiteliaaliset
- Neuroektodermaaliset kasvaimet
- Neoplasmat, sukusolut ja alkiot
- Kasvaimet, hermokudos
- Hermoston kasvaimet
- Munuaisten kasvaimet
- Sylkirauhasten sairaudet
- Neoplastiset oireyhtymät, perinnölliset
- Neoplasmat, side- ja pehmytkudokset
- Neuroektodermaaliset kasvaimet, primitiiviset, perifeeriset
- Neuroektodermaaliset kasvaimet, primitiiviset
- Osteosarkooma
- Kasvaimet, luukudos
- Kasvaimet, sidekudos
- Neoplasmat, monimutkaiset ja sekamuotoiset
- Kilpirauhasen sairaudet
- Adenokarsinooma, papillaarinen
- Suun kasvaimet
- Synnynnäiset, perinnölliset ja vastasyntyneiden sairaudet ja poikkeavuudet
- Patologiset tilat, merkit ja oireet
- Kilpirauhassyöpä, papillaari
- Toistuminen
- Neoplasman metastaasit
- Glioma
- Neuroblastooma
- Sarkooma, Ewing
- Sarkooma
- Aivojen kasvaimet
- Keskushermoston kasvaimet
- Medulloblastooma
- Wilmsin kasvain
- Nefroma, mesoblastinen
- Sylkirauhasten kasvaimet
- entrektinibi
Muut tutkimustunnusnumerot
- RXDX-101-03
- CO40778 (Muu tunniste: Hoffmann-La Roche)
- 2023-505088-35-00 (Ctis)
- 2023 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .